

Ann Marie Navar-Boggan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5362070/publications.pdf>

Version: 2024-02-01

139
papers

5,628
citations

126858

33
h-index

91828

69
g-index

144
all docs

144
docs citations

144
times ranked

8063
citing authors

#	ARTICLE	IF	CITATIONS
1	The Potential and Pitfalls of Coronary Artery Calcium Scoring. <i>JAMA Cardiology</i> , 2022, 7, 11.	3.0	6
2	Underdiagnosis of familial hypercholesterolaemia: innovation is overdue. <i>European Heart Journal</i> , 2022, 43, 3255-3257.	1.0	5
3	Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized controlled trials. <i>Progress in Cardiovascular Diseases</i> , 2022, 73, 48-55.	1.6	19
4	Managing Atherosclerotic Cardiovascular Risk in Young Adults. <i>Journal of the American College of Cardiology</i> , 2022, 79, 819-836.	1.2	72
5	Trends of blood pressure control in the U.S. during the COVID-19 pandemic. <i>American Heart Journal</i> , 2022, 247, 15-23.	1.2	40
6	Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 383-392.	0.9	6
7	Communicating the Benefits of Vaccination in Light of Potential Risks. <i>JAMA Cardiology</i> , 2022, 7, 612.	3.0	2
8	Limitations of Observational Studies for Aspirin in Primary Prevention and the Need for Randomized Trials. <i>Radiology: Cardiothoracic Imaging</i> , 2022, 4, e220079.	0.9	0
9	Machine Learning-Based Models Incorporating Social Determinants of Health vs Traditional Models for Predicting In-Hospital Mortality in Patients With Heart Failure. <i>JAMA Cardiology</i> , 2022, 7, 844.	3.0	28
10	Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries. <i>JAMA Cardiology</i> , 2021, 6, 92-96.	3.0	10
11	Association of Medicaid Expansion With Rates of Utilization of Cardiovascular Therapies Among Medicaid Beneficiaries Between 2011 and 2018. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007492.	0.9	13
12	Can the Absence of Hypertension Refine the Risk Assessment of Older Adults for Future Cardiovascular Events?. <i>American Journal of Cardiology</i> , 2021, 142, 83-90.	0.7	0
13	The Changing Profile of Autopsies in Cardiovascular Deaths in the United States, 2003-2018. <i>American Journal of Cardiology</i> , 2021, 140, 150-151.	0.7	0
14	Patient-Perceived Versus Actual Risk of Cardiovascular Disease and Associated Willingness to Consider and Use Prevention Therapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006548.	0.9	20
15	New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1564-1575.	1.2	49
16	The incremental value of angiographic features for predicting recurrent cardiovascular events: Insights from the Duke Databank for Cardiovascular Disease. <i>Atherosclerosis</i> , 2021, 321, 1-7.	0.4	1
17	Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2021, 10, e019636.	1.6	80
18	Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease. <i>Journal of the American Heart Association</i> , 2021, 10, e019331.	1.6	19

#	ARTICLE	IF	CITATIONS
19	Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans. <i>Journal of the American Heart Association</i> , 2021, 10, e019254.	1.6	11
20	Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. adults. <i>PLoS ONE</i> , 2021, 16, e0251963.	1.1	56
21	Is Coronary Calcium Scanning the “Secret Sauce” for Affordable Atherosclerotic Cardiovascular Disease Primary Prevention Trials?. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1017-1019.	2.3	3
22	Patient perceptions and use of non-statin lipid lowering therapy among patients with or at risk for atherosclerotic cardiovascular disease: Insights from the PALM registry. <i>Clinical Cardiology</i> , 2021, 44, 863-870.	0.7	2
23	U.S. population at increased risk of severe illness from COVID-19. <i>American Journal of Preventive Cardiology</i> , 2021, 6, 100156.	1.3	19
24	Prospective evaluation of lipid management following acute coronary syndrome in non-Western countries. <i>Clinical Cardiology</i> , 2021, 44, 955-962.	0.7	5
25	Temporal Associations Between Immunization With the COVID-19 mRNA Vaccines and Myocarditis. <i>JAMA Cardiology</i> , 2021, 6, 1117.	3.0	12
26	Incremental Benefits of Machine Learning “When Do We Need a Better Mousetrap?”. <i>JAMA Cardiology</i> , 2021, 6, 621.	3.0	15
27	Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, 2009-2022.	2.9	19
28	Extrapolating Survival From Randomized Clinical Trial Data “Possibilities and Caution. <i>JAMA Cardiology</i> , 2021, 6, 1305.	3.0	2
29	The impact of race and ethnicity on outcomes in 19,584 adults hospitalized with COVID-19. <i>PLoS ONE</i> , 2021, 16, e0254809.	1.1	19
30	The Cumulative Impact of Chronic Stressors on Risks for Myocardial Infarction in U.S. Older Adults. <i>Psychosomatic Medicine</i> , 2021, Publish Ahead of Print, 987-994.	1.3	1
31	Transforming the Paradigm for Lipid Lowering. <i>JAMA Cardiology</i> , 2021, , .	3.0	2
32	Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: An ASPC practice statement. <i>American Journal of Preventive Cardiology</i> , 2021, 8, 100250.	1.3	51
33	Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system. <i>Journal of Clinical Lipidology</i> , 2021, 15, 832-839.	0.6	4
34	Asian Pacific Society of Cardiology Consensus Recommendations on Dyslipidaemia. <i>European Cardiology Review</i> , 2021, 16, e54.	0.7	10
35	The Accuracy of Cardiovascular Pooled Cohort Risk Estimates in U.S. Older Adults. <i>Journal of General Internal Medicine</i> , 2020, 35, 1701-1708.	1.3	31
36	Questioning the Benefit of Statins for Low-Risk Populations “Medical Misinformation or Scientific Evidence?” Reply. <i>JAMA Cardiology</i> , 2020, 5, 233.	3.0	0

#	ARTICLE	IF	CITATIONS
37	Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 336.	3.0	16
38	Association Between Triglycerides and Residual Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease (From the Bypass Angioplasty Revascularization) <i>Tj ETQq0 0 0 rgBT, Overlock 710 Tf 50 6</i>	1.0	0
39	Performance of Guideline Recommendations for Prevention of Myocardial Infarction in Young Adults. <i>Journal of the American College of Cardiology</i> , 2020, 76, 653-664.	1.2	39
40	Choosing an Initial Therapeutic Approach for Hypertension—Time for a Fixed-Dose Combination First?. <i>JAMA Cardiology</i> , 2020, 5, 1217.	3.0	0
41	Representation of Older Adults in Cardiovascular Disease Trials Since the Inclusion Across the Lifespan Policy. <i>JAMA Internal Medicine</i> , 2020, 180, 1531.	2.6	23
42	Teaching Old Treatments New Tricks. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009725.	1.4	0
43	Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statin-Associated Side Effects. <i>Journal of the American Heart Association</i> , 2020, 9, e017915.	1.6	14
44	Prevalence, treatment, and control of severe hyperlipidemia. <i>American Journal of Preventive Cardiology</i> , 2020, 3, 100079.	1.3	5
45	County-level phenomapping to identify disparities in cardiovascular outcomes: An unsupervised clustering analysis. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100118.	1.3	3
46	Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology. <i>American Journal of Preventive Cardiology</i> , 2020, 1, 100009.	1.3	90
47	Heroism in the Face of the COVID-19 Pandemic. <i>JAMA Cardiology</i> , 2020, 5, 1163.	3.0	0
48	Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin. <i>Journal of the American College of Cardiology</i> , 2020, 75, 835-837.	1.2	1
49	Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006019.	0.9	7
50	Association of Blood Pressure Patterns in Young Adulthood With Cardiovascular Disease and Mortality in Middle Age. <i>JAMA Cardiology</i> , 2020, 5, 382.	3.0	35
51	Beliefs, risk perceptions, and lipid management among patients with and without diabetes: Results from the PALM registry. <i>American Heart Journal</i> , 2020, 225, 88-96.	1.2	8
52	High Rates of Off-label Prescribing and the Urgent Need for a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2020, 5, 692.	3.0	2
53	Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. <i>American Journal of Cardiology</i> , 2020, 126, 94-102.	0.7	25
54	Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020. <i>Journal of Women's Health</i> , 2020, 29, 1091-1100.	1.5	9

#	ARTICLE	IF	CITATIONS
55	Chronic Stress and Risks for Myocardial Infarction in U.S. Adults. <i>Innovation in Aging</i> , 2020, 4, 394-395.	0.0	2
56	Regional Differences in Secondary Prevention Therapy—Geography Should Not Be Destiny. <i>JAMA Cardiology</i> , 2019, 4, 873.	3.0	1
57	The Association Between Low-Density Lipoprotein Cholesterol and Incident Atherosclerotic Cardiovascular Disease in Older Adults: Results From the National Institutes of Health Pooled Cohorts. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 2560-2567.	1.3	26
58	PATIENT PERCEPTIONS AND MANAGEMENT OF CHOLESTEROL AMONG INDIVIDUALS WITH OR WITHOUT DIABETES IN COMMUNITY PRACTICE: RESULTS FROM THE PALM REGISTRY. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1710.	1.2	0
59	The patient journey with proprotein convertase subtilisin/kexin type 9 inhibitors in community practice. <i>Journal of Clinical Lipidology</i> , 2019, 13, 725-734.	0.6	21
60	Sex Differences in the Use of Statins in Community Practice. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005562.	0.9	155
61	Impediments to Implementing Guideline-Directed Medical Therapies. <i>JAMA Cardiology</i> , 2019, 4, 830.	3.0	4
62	Fear-Based Medical Misinformation and Disease Prevention. <i>JAMA Cardiology</i> , 2019, 4, 723.	3.0	25
63	Trajectories of Non-HDL Cholesterol Across Midlife. <i>Journal of the American College of Cardiology</i> , 2019, 74, 70-79.	1.2	67
64	Apolipoprotein B Particles and Cardiovascular Disease. <i>JAMA Cardiology</i> , 2019, 4, 1287.	3.0	299
65	Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e013229.	1.6	11
66	Blood Pressure Assessment in Adults—Clinical Practice and Clinic-Based Research. <i>Journal of the American College of Cardiology</i> , 2019, 73, 317-335.	1.2	114
67	The Evolving Story of Triglycerides and Coronary Heart Disease Risk. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 347.	3.8	30
68	Association of Primary Care Providers' Beliefs of Statins for Primary Prevention and Statin Prescription. <i>Journal of the American Heart Association</i> , 2019, 8, e010241.	1.6	23
69	TRIGLYCERIDES AS A RISK FACTOR FOR CORONARY HEART DISEASE: WHAT MEASURE AND WHAT CUTOFF?. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1865.	1.2	4
70	Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry. <i>American Heart Journal</i> , 2019, 214, 113-124.	1.2	17
71	PRACTICE-LEVEL VARIATION IN STATIN USE AND LDL-C CONTROL IN THE UNITED STATES: RESULTS FROM THE PATIENT AND PROVIDER ASSESSMENT OF LIPID MANAGEMENT (PALM) REGISTRY. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1706.	1.2	0
72	Evaluation of Mortality Data From the Social Security Administration Death Master File for Clinical Research. <i>JAMA Cardiology</i> , 2019, 4, 375.	3.0	43

#	ARTICLE	IF	CITATIONS
73	Patient-Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e011765.	1.6	139
74	Electronic Health Record Data Quality Issues Are Not Remedied by Increasing Granularity of Diagnosis Codes. <i>JAMA Cardiology</i> , 2019, 4, 465.	3.0	7
75	Statins Work, but Only in People Who Take Them. <i>JAMA Cardiology</i> , 2019, 4, 214.	3.0	3
76	Some patient interventions increased thiazide prescriptions and improved blood pressure control. <i>Annals of Internal Medicine</i> , 2019, 170, JC46.	2.0	2
77	Evaluating the Impact of Interruptive Alerts within a Health System: Use, Response Time, and Cumulative Time Burden. <i>Applied Clinical Informatics</i> , 2019, 10, 909-917.	0.8	17
78	Association of Clinician Knowledge and Statin Beliefs With Statin Therapy Use and Lipid Levels (A) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i>	0.7	16
79	Medication Discontinuation in the IMPROVE-IT Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005041.	0.9	23
80	Quantifying Importance of Major Risk Factors for Coronary Heart Disease. <i>Circulation</i> , 2019, 139, 1603-1611.	1.6	115
81	Challenges in Interpreting the Lipid-Lowering Trials. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1549.	3.8	10
82	An Observational Study of the Association of Video- Versus Text-Based Informed Consent With Multicenter Trial Enrollment. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004675.	0.9	20
83	Lipid Testing and Statin Dosing After Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	22
84	Improving patient risk communication: Translating cardiovascular risk into standardized risk percentiles. <i>American Heart Journal</i> , 2018, 198, 18-24.	1.2	12
85	Does clinician-reported lipid guideline adoption translate to guideline-adherent care? An evaluation of the Patient and Provider Assessment of Lipid Management (PALM) registry. <i>American Heart Journal</i> , 2018, 200, 118-124.	1.2	14
86	Prevalence and Management of Symptoms Associated With Statin Therapy in Community Practice. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004249.	0.9	24
87	Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project. <i>American Heart Journal</i> , 2018, 195, 151-152.	1.2	11
88	A case of spontaneous coronary artery dissection diagnosed by coronary computed tomography angiography. <i>Journal of Cardiovascular Computed Tomography</i> , 2018, 12, 88-89.	0.7	7
89	Availability and Use of Shared Data From Cardiometabolic Clinical Trials. <i>Circulation</i> , 2018, 137, 938-947.	1.6	17
90	Influence of Cardiovascular Risk Communication Tools and Presentation Formats on Patient Perceptions and Preferences. <i>JAMA Cardiology</i> , 2018, 3, 1192.	3.0	48

#	ARTICLE	IF	CITATIONS
91	Measurement of Low-Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry. <i>Journal of the American Heart Association</i> , 2018, 7, e009251.	1.6	9
92	Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	49
93	Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use. <i>JAMA Cardiology</i> , 2018, 3, 739.	3.0	94
94	Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges. <i>European Heart Journal</i> , 2017, 38, ehw302.	1.0	276
95	Opportunities and challenges in developing risk prediction models with electronic health records data: a systematic review. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017, 24, 198-208.	2.2	569
96	The Complexities of Hypertension. <i>JAMA Cardiology</i> , 2017, 2, 389.	3.0	1
97	Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1563.	3.8	49
98	Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017, 136, 1193-1203.	1.6	47
99	RECURRENT CARDIOVASCULAR EVENT RATES IN A CONTEMPORARY COHORT OF 829,498 ADULTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE. <i>Journal of the American College of Cardiology</i> , 2017, 69, 59.	1.2	2
100	Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy. <i>JAMA Cardiology</i> , 2017, 2, 1217.	3.0	100
101	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events. <i>Hypertension</i> , 2017, 70, 907-914.	1.3	12
102	“Sticky” Issues for Adherence in Secondary Prevention. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1555-1557.	1.2	3
103	Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry. <i>American Heart Journal</i> , 2017, 193, 84-92.	1.2	55
104	Statin Eligibility Under American and European Cholesterol Guidelines—Reply. <i>JAMA Cardiology</i> , 2017, 2, 460.	3.0	0
105	Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States. <i>JAMA Cardiology</i> , 2016, 1, 700.	3.0	13
106	In patients with MI, new-onset or existing AF increased risk for CV events at 90 days. <i>Annals of Internal Medicine</i> , 2016, 164, JC66.	2.0	1
107	Assessing Cardiovascular Risk to Guide Hypertension Diagnosis and Treatment. <i>JAMA Cardiology</i> , 2016, 1, 864.	3.0	29
108	Risk Prediction With Electronic Health Records. <i>JAMA Cardiology</i> , 2016, 1, 976.	3.0	25

#	ARTICLE	IF	CITATIONS
109	Open Access Platforms for Sharing Clinical Trial Data—Reply. JAMA - Journal of the American Medical Association, 2016, 316, 666.	3.8	1
110	Research Needs to Improve Hypertension Treatment and Control in African Americans. Hypertension, 2016, 68, 1066-1072.	1.3	78
111	Temporal Changes in the Association Between Modifiable Risk Factors and Coronary Heart Disease Incidence. JAMA - Journal of the American Medical Association, 2016, 316, 2041.	3.8	30
112	Evolving Approaches for Statins in Primary Prevention. JAMA - Journal of the American Medical Association, 2016, 316, 1981.	3.8	4
113	What to say and how to say it. Current Opinion in Cardiology, 2016, 31, 537-544.	0.8	28
114	Use of Open Access Platforms for Clinical Trial Data. JAMA - Journal of the American Medical Association, 2016, 315, 1283.	3.8	57
115	An Approach to Improve the Negative Predictive Value and Clinical Utility of Transthoracic Echocardiography in Suspected Native Valve Infective Endocarditis. Journal of the American Society of Echocardiography, 2016, 29, 315-322.	1.2	24
116	Using Seroprevalence and Immunisation Coverage Data to Estimate the Global Burden of Congenital Rubella Syndrome, 1996-2010: A Systematic Review. PLoS ONE, 2016, 11, e0149160.	1.1	170
117	Cardiovascular care for older adults: hypertension and stroke in the older adult. Journal of Geriatric Cardiology, 2016, 13, 373-9.	0.2	6
118	Response to Letter Regarding Article, "Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease." Circulation, 2015, 132, e203.	1.6	2
119	Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease. Circulation, 2015, 131, 451-458.	1.6	283
120	Using Age- and Sex-Specific Risk Thresholds to Guide Statin Therapy. Journal of the American College of Cardiology, 2015, 65, 1633-1639.	1.2	58
121	Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry. American Heart Journal, 2015, 170, 865-871.	1.2	20
122	Application of the New Cholesterol Guidelines. New England Journal of Medicine, 2014, 371, 77-79.	13.9	6
123	Proportion of US Adults Potentially Affected by the 2014 Hypertension Guideline. JAMA - Journal of the American Medical Association, 2014, 311, 1424.	3.8	95
124	Patients Affected by Changes to Hypertension Guideline—Reply. JAMA - Journal of the American Medical Association, 2014, 312, 846.	3.8	2
125	Application of New Cholesterol Guidelines to a Population-Based Sample. New England Journal of Medicine, 2014, 370, 1422-1431.	13.9	571
126	The impact of a measurement and feedback intervention on blood pressure control in ambulatory cardiology practice. American Heart Journal, 2014, 167, 466-471.	1.2	4

#	ARTICLE	IF	CITATIONS
127	Reductions in telemetry order duration do not reduce telemetry utilization. <i>Journal of Hospital Medicine</i> , 2014, 9, 795-796.	0.7	7
128	Variability in performance measures for assessment of hypertension control. <i>American Heart Journal</i> , 2013, 165, 823-827.	1.2	8
129	The feasibility and accuracy of evaluating lipid management performance metrics using an electronic health record. <i>American Heart Journal</i> , 2013, 166, 701-708.	1.2	9
130	Are Recent Medical Graduates More Skeptical of Vaccines?. <i>Vaccines</i> , 2013, 1, 154-166.	2.1	19
131	Hypertension Control Among Patients Followed by Cardiologists. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 352-357.	0.9	12
132	Pediatric-Specific Antimicrobial Susceptibility Data and Empiric Antibiotic Selection. <i>Pediatrics</i> , 2012, 130, e615-e622.	1.0	39
133	A High-Dose Continuous Haloperidol Infusion Successfully Controlled Intractable Terminal Delirium (748). <i>Journal of Pain and Symptom Management</i> , 2011, 41, 301-302.	0.6	0
134	Disparities in preschool immunization coverage associated with maternal age. <i>Hum Vaccin</i> , 2009, 5, 557-561.	2.4	11
135	Vaccine knowledge and practices of primary care providers of exempt vs. vaccinated children. <i>Hum Vaccin</i> , 2008, 4, 286-291.	2.4	50
136	Prenatal Immunization Education. <i>American Journal of Preventive Medicine</i> , 2007, 33, 211-213.	1.6	29
137	Nonmedical Exemptions to School Immunization Requirements. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 1757.	3.8	337
138	Measuring Immunization Coverage among Preschool Children: Past, Present, and Future Opportunities. <i>Epidemiologic Reviews</i> , 2006, 28, 27-40.	1.3	34
139	Simultaneous Single-Particle Tracking and Visualization of Domain Structure on Lipid Monolayers. <i>Langmuir</i> , 2003, 19, 4876-4879.	1.6	19